I Know First Review: July 16th, 2015

I Know First Review

The stocks selected here are the top performing stocks from I Know First: Daily Market Forecast’s June 22nd, 2015 stock forecast titled “Quantitative finance: Up to 28% In 1 Month“.

This forecast is part of the “Biotech Stocks” package, as one of I Know First’s quantitative investment solutions. The “I Know First Average” return was 8.52% over 1 month versus the S&P 500’s return of 0.63% over the same time period.

I Know First Review

Learn how to read the predictions: Instructions

Learn how to strategise with the forecast: Algorithmic Trading Strategies 

Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.


 Signal: 47.19

 Predictability: 0.34

 Return:  -15.60%

Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focused on the research, development, and commercialisation of engineered DNA-binding proteins as novel therapeutic products for various monogenic and infectious diseases with unmet medical needs.


     Signal: 44.26

     Predictability: 0.24

     Return: 28%


Kite Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialisation of novel cancer immunotherapy products. The company is developing a pipeline of engineered autologous cell therapy-based product candidates for the treatment of solid and haematological malignancies.

The company had a signal strength of 44.26 and a predictability indicator of 0.24. In accordance with the algorithm’s prediction, the stock price increased 28%.

Kite Pharma Inc. has just signed up with bluebird bio, Inc. BLUE for the development and commercialisation of second generation T cell receptor; bluebird’s expertise is in gene editing and its lentiviral vector platform will be combined with Kite Pharma’s TCR capabilities for the co-development and co-commercialization of second generation TCR candidates. This early commercial agreement is good news for the company itself and its investors; the agreement will improve the ability for both the two companies to be effective in their research programs and what’s more extend their mutual commercial network. As the return of the stock is that high, investors have probably anticipated the news which was probably spreading around before the official announcement. For those reasons for the next weeks we should expect a down-sizing of the price, or at least an average moving around its target price.

 Signal: 40.59

 Predictability: 0.18

 Return: 7.37%


Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercialising small molecule drugs for patients with serious diseases in specialty markets. The company focuses on developing and commercialising therapies for the treatment of cystic fibrosis (CF); and advancing its research and early-stage development programs.

The company had a signal strength of 40.59 and a predictability indicator of 0.18. In accordance with the algorithm’s prediction, the stock price increased 7.37%.

Vertex Pharmaceuticals Incorporated announced that Sangeeta N. Bhatia, M.D., Ph.D., joined its board of directors as an independent director. “Dr. Bhatia is a leading physician scientist and medical researcher who brings a wealth of expertise to our board,” said Jeffrey Leiden, M.D., Ph.D., Chairman, President and Chief Executive Officer of Vertex. “Her extensive experience in the field of biomedical engineering and in-depth understanding on the use of advanced technologies in medical research will provide valuable insights to our board and our company as we advance key research and development programs. On top of that the company announced that the U.S. Food and Drug Administration (FDA) approved its pipeline drug, Orkambi. For the first time in history, there is a medicine to treat the underlying cause of the most common form of cystic fibrosis (CF). Realizing the possible benefits of the drug, analysts are continuing to shed light on Vertex’s future. The stock price increased significantly since those 2 announcements, our insight is that the FDA approval weighs much more in the rise of the stock price, as it constitutes an acknowledgement of the company’s forwarding research always oriented in peering for new innovative treatments and solutions.


 Signal: 39.37

 Predictability: 0.25

 Return: 3.63%

Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products.

The company had a signal strength of 39.37 and a predictability indicator of 0.25. In accordance with the algorithm’s prediction, the stock price increased 3.63%.

In order to acquire new and specific competences and skills in the biopharmaceutical market, Shire plc is currently leading a research campaign oriented in finding new innovative biotech firms to start new acquisitions; the company is focused and determined in a new wave of market expansion and to do so it has to buy little innovative firms. Thus the expectations remain solid and hopeful for the next future survival of Shire in the quite ultra competitive biotech field.


  Predictability: 0.14

  Return: 5.59%


Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and preparing to commercialise medicines paired with companion diagnostics for the treatment of cancer primarily in the United States.

The company had a signal strength of 39.12 and a predictability indicator of 0.14. In accordance with the algorithm’s prediction, the stock price increased 5.59%.

Merrimack Pharmaceuticals Inc. announced the initiation of clinical imaging assessing the use of a potential marker for delivery of MM-398 (irinotecan liposome injection), also known as “nal-IRI,” to metastatic breast cancer. This study is an expansion of a Phase 1 pilot study which assessed the feasibility of using ferumoxytol*, an iron oxide nanoparticle, to act as a marker for MM-398 tumor response prediction. The study will now enroll patients who have metastatic breast cancer which is either hormone receptor-positive, triple-negative, or where active brain metastases are present. Obtaining new and promising research results is the key for a biotech firm ad Merrimack to have success and secure cheap money from the investors.


Predictability: 0.29

 Return: 20.16%

XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific.

The company had a signal strength of 35.94 and a predictability indicator of 0.29. In accordance with the algorithm’s prediction, the stock price increased 20.16%.

The recent monthly earnings report of XOMA Corp were quite promising for the road to a good overall annual performance. The reports underlined the fact that the trend since the last 2 years is positive and should continue on the same option; on the practical side XOMA announced XOMA 358, a fully human allosteric monoclonal antibody that reduces both the binding of insulin to its receptor and downstream insulin signaling, has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of congenital hyperinsulinism (HI).

Signal : 32.55

Predictability : 0.50

Return: 2.81%

Exelixis, Inc., a biopharmaceutical company, develops and sells small molecule therapies for the treatment of cancer in the United States. The company offers COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of patients with progressive, metastatic medullary thyroid cancer.

The company had a signal strength of 32.55 and a predictability indicator of 0.50. In accordance with the algorithm’s prediction, the stock price increased 2.81%.

What do analysts think? From their insights Exelixis Inc. has received a hold rating for the short term, according to the rank of 3 from Zacks research firm. The shares could manage an average rating of 2.5 from 4 analysts. 1 market experts have marked it as a strong buy. 3 analysts have rated the company at hold. Exelixis, Inc. announced the initiation of a phase 1 trial of cabozantinib in combination with nivolumab alone or in combination with nivolumab plus ipilimumab in patients with advanced/metastatic urothelial (bladder) and other genitourinary tumors. The latest news are quite encouraging, but as biotech and in general pharmaceutical companies often find some new scientific progresses to announce to their investors platea, the “investor’s community” is waiting for tangible and concrete market results to eventually start strong buying EXEL on the stock market.

  Signal: 32.52

  Predictability: 0.37

  Return: 19.89%

BioMarin Pharmaceutical Inc. develops and commercialises pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally.

The company had a signal strength of 32.52 and a predictability indicator of 0.37. In accordance with the algorithm’s prediction, the stock price increased 19.89%.

New following positive midstage trial results came up and are being released for Biomarin’s BMN-111, a treatment for children with achondroplasia, which is the most common form of human dwarfism. BioMarin Pharmaceutical is one of the most successful developers of therapies for rare disease and the results from this trial suggest that BMN-111 could end up being yet another important win for the company, this is also due to the proven serious behaviour of the company’s announcing campaigns; if over the last month the stock price has increased so much it is why there are real expectations behind the midstage trials and not only hopeful expectations; the next weeks and months will probably bring to confirm nowadays undergoing expectations.

Signal : 22.55

Predictability : 0.30

Return: 3.97%

Bio-Techne Corporation develops, manufactures, and sells biotechnology products and clinical diagnostic controls worldwide. It operates in two segments, Biotechnology and Clinical Controls.

The company had a signal strength of 22.55 and a predictability indicator of 0.30. In accordance with the algorithm’s prediction, stock price increased by 3.97%.

Sell-side Wall Street analysts are anticipating Bio-Techne Corp will post a current quarter earnings per share of $0.87. This figure is based on the combined estimates of the analysts that cover the company. For the period ending on 2015-03-31 the company reported earnings per share of $0.86. Based on the latest public information, the firm is slated to next report earnings on or around 2015-08-10. Worldwide investors are willing to see if the analyst’s expectations will be met in the next report, meanwhile some of them have already started to go forward and buy some stocks in order to profit from a higher increase in the stock price, plus the expected earning per share.


   Signal: 22.01

   Predictability: 0.29

   Return: 9.38%

The investment seeks capital appreciation. The fund invests primarily in common stocks. It normally invests at least 80% of assets in securities of companies principally engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes and companies that benefit significantly from scientific and technological advances in biotechnology.

The company had a signal strength of 22.01 and a predictability indicator of 0.29. In accordance with the algorithm’s prediction, stock price increased by 9.38%.

As the overall biotech and pharmaceutical sector is going well and the average stock returns are satisfying, it is as simple as it seems that also the part of Fidelity Investments which has a dedicated biotech fund is experiencing a profitable period for both investors and Biotech industries.

Business Disclosure: I Know First Research is the analytic branch of I Know First, a financial startup company that specialises in quantitatively predicting the stock market. We did not receive compensation for this article, and we have no business relationship with any company whose stock is mentioned in this article. Read More From I Know First Research:

  • Electric Buses Vs. Fuel Cell Buses: Plug Power Has A Stake In The Winner (View)
  • Why BlackBerry Holds Long-Term Value For Investors (View)
  • Tata Motors Is An Attractive Opportunity: An Algorithmic Analysis (View)
  • Applied Material’s Venture Group Invests Into UV LED, An Interesting Portfolio Expansion With Growth Potential (View)
  • Can Apollo Fight Online Education Any Longer? (View)